Syndax Pharma Names Steve Sabus Chief Commercial Officer, Effective Dec. 5

Syndax Pharmaceuticals, Inc. (SNDX), a clinical-stage biopharmaceutical company developing cancer therapies, announced Friday the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5.

Sabus holds more than 30 years of commercial experience launching drugs and building sales and marketing organizations within the biopharmaceutical industry.

As Chief Commercial Officer, he will oversee all commercial functions, including the development of critical launch initiatives, sales planning and commercial strategy.

Prior to joining Syndax, Sabus served as Chief Commercial Officer at Turning Point Therapeutics, before being acquired by BMS. Before that he held senior commercial roles at Astellas Pharma for over 15 years, most recently serving as the Head of Oncology.

Before Astellas, Sabus spent 16 years at Johnson & Johnson in commercial roles of increasing responsibility.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT